


Claims

1. Use of a compound of Formula (I):




wherein

10 A is a bond, a NH, O, S, SO, SO₂, SO₂NH, PO₄, -NH-CO-NH-, -CO-NH-, -CO-, -CO-O-, -NH-CO-O-, -O-Z-heterocycloalkylen, an alkylen group, an alkenylen group, an alkinylen group, a heteroalkylen group, an arylen group, a heteroarylen group, a cycloalkylen group, a heterocycloalkylen group, an alkylarylen group or a heteroarylalkylen group or a combination of two or more of these atoms or groups;

15

L is selected from the following groups:

20



X is CR₅ or N;

Y is CR₆ or N;

5

U is F or Cl;

10 Z is a C₁₋₄ alkylene group, a C₂₋₄ alkenylene group, a C₂₋₄ alkynylene group or a C₁₋₄ heteroalkylene group, all of which may be substituted by one or more hydroxy or amino groups;

n is 0, 1, 2 or 3;

15 R₁ is H, F, Cl, Br, I, OH, NH₂, an alkyl group or a heteroalkyl group;

R₂ is H, F or Cl;

20 R₃ is H, an alkyl group, an alkenyl group, an alkinyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkylaryl group or a heteroarylalkyl group; all of which may be substituted with one, two or more halogen atoms like F or Cl;

25 R₄ is a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkylaryl group or a heteroarylalkyl group;

30

R5 is H, F, Cl, OH, NH₂, an alkyl group or a heteroalkyl group, or

5 R3 and R5 can be linked via an alkylen, an alkenylen or a heteroalkylen group or be a part of a cycloalkylen or heterocyclo-alkylen group; in case R3 is no H and R5 is no H, F, OH, NH₂ or Cl;

10 R6 is H, F, Cl or OMe;

R8 is a C₁₋₆ heteroalkyl or a heteroarylalkyl group;

15 or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof for the treatment of anthrax.

2. Use of a compound according to Claim 1, wherein R1 is H.

3. Use of a compound according to Claim 1 or 2, wherein R2 is F or H.

20 4. Use of a compound according to any one of the preceding claims, wherein R3 is an ethyl, a 2-propyl, a C₃-C₆ cycloalkyl, a phenyl or a pyridyl group, all of which may be substituted by one, two or more fluorine atoms or
25 amino groups.

5. Use of a compound according to any one of the preceding claims, wherein R3 is a cyclopropyl group.

6. Use of a compound according to any one of the preceding claims, wherein R3 and R5 together form a group of the formula -O-CH₂-N(Me)- or -O-CH₂-CH(Me)-.
- 5 7. Use of a compound according to any one of the preceding claims, wherein R4 is an acetylamino group.
8. Use of a compound according to any one of the preceding claims, wherein the absolute configuration at C-5 of the 10 oxazolidinone ring is (S) according to the Cahn-Ingold-Prelog nomenclature system.
9. Use of a compound according to any one of the preceding claims, wherein X is N or CH.
- 15 10. Use of a compound according to any one of the preceding claims, wherein Y is CF or CH.
11. Use of a compound according to any one of the preceding 20 claims, wherein n is 0.
12. Use of a compound according to any one of claims 1-11, wherein A is a group of the formula

25 -B₀₋₁ [D - E₀₋₁]_m - G₀₋₁ - K₀₋₁-

wherein

30 the group B is an alkylene, which may be substituted by one, two or more fluorine atoms, an O, S, SO, SO₂, SO₂NH group, or a heteroalkylen group, which may be substituted

by one, two or more fluorine atoms and/or at the optionally present nitrogen atoms by an alkyl or an acyl group;

5 the groups D independently of each other are optionally anellated heterocycloalkylen groups with 1, 2, 3 or 4 nitrogen atoms, which heterocycloalkylen groups may each be substituted by one, two or more fluorine atoms and/or which each may be substituted at one, two, three or four 10 nitrogen atoms by an alkyl or an acyl group;

15 the groups E independently of each other are an alkylene, which may be substituted by one, two or more fluorine atoms, an O, S, SO, SO₂, SO₂NH group, or a heteroalkylen group, which may be substituted by one, two or more 20 fluorine atoms and/or at the optionally present nitrogen atoms by an alkyl or an acyl group;

25 the groups G independently of each other are optionally anellated heterocycloalkylen groups with 1, 2, 3 or 4 nitrogen atoms, which heterocycloalkylen groups may each be substituted by one, two or more fluorine atoms and/or which each may be substituted at one, two, three or four 30 nitrogen atoms by an alkyl or an acyl group; .

25 the group K is an alkylene, which may be substituted by one, two or more fluorine atoms, an O, S, SO, SO₂, SO₂NH group, or a heteroalkylen group, which may be substituted by one, two or more fluorine atoms and/or at the 30 optionally present nitrogen atoms by an alkyl or an acyl group; and m = 1,2,3 or 4.

13. Use of a compound according to any one of Claims 1-11, wherein A is a group of the formula -V-W-, wherein V is a direct bond or a group of the formula NH, O, S, SO, SO₂, SO₂NH, PO₄, -NH-CO-NH-, -CO-NH-, -CO-, -CH₂-, -CO-O-, -(CH₂)₁₋₃-O-, -CH=CH-C(O)-, or -NH-CO-O- and W is a heterocycloalkyl group with 4 to 7 ring atoms or a alkylheterocycloalkyl group with 4 to 7 ring atoms and 1 to 4 carbon atoms in the alkyl chain; all these groups may be substituted by 1, 2, 3 or 4 fluorine atoms, methyl or methoxy groups.

14. Use of a compound according to any one of Claims 1-11, wherein A is a group of the formula

15.
$$\begin{array}{c} \vdots \\ \text{V} - (\text{CH}_2)_a \text{---} \text{C} \begin{array}{c} \text{(CH}_2\text{)}_b \\ \diagdown \\ \text{N} \end{array} \text{---} \vdots \\ \text{(CH}_2\text{)}_c \end{array}$$


wherein

20. V is a group of the formula NH, O, S, SO, SO₂, SO₂NH, PO₄, -NH-CO-NH-, -CO-NH-, -CO-, -CH₂-, -CO-O-, -(CH₂)₁₋₃-O-, -CH=CH-C(O)-, or -NH-CO-O-; a is 0, 1, 2, 3 or 4; b is 0, 1, 2, 3 or 4; c is 0, 1, 2, 3 or 4 and 1, 2, 3 or 4 hydrogen atoms may be substituted by F, a methyl- or a methoxy group.

25. Use of a compound according to Claims 13 or 14, wherein V is NH, O, S, SO or SO₂.

13. Use of a compound according to any one of Claims 1-11, wherein A is a group of the formula -V-W-, wherein V is a direct bond or a group of the formula NH, O, S, SO, SO₂, SO₂NH, PO₄, -NH-CO-NH-, -CO-NH-, -CO-, -CH₂-, -CO-O-, -(CH₂)₁₋₃-O-, -CH=CH-C(O)-, or -NH-CO-O- and W is a heterocycloalkyl group with 4 to 7 ring atoms or a alkylheterocycloalkyl group with 4 to 7 ring atoms and 1 to 4 carbon atoms in the alkyl chain; all these groups may be substituted by 1, 2, 3 or 4 fluorine atoms, methyl or methoxy groups.

14. Use of a compound according to any one of Claims 1-11, wherein A is a group of the formula



wherein

20 v is a group of the formula NH, O, S, SO, SO₂, SO₂NH, PO₄,
-NH-CO-NH-, -CO-NH-, -CO-, -CH₂-, -CO-O-, -(CH₂)₁₋₃-O-,
-CH=CH-C(O)-, or -NH-CO-O-; a is 0, 1, 2, 3 or 4; b is 0,
1, 2, 3 or 4; c is 0, 1, 2, 3 or 4 and 1, 2, 3 or 4
hydrogen atoms may be substituted by F, a methyl- or a
methoxy group.


25


15. Use of a compound according to Claims 13 or 14, wherein V is NH, O, S, SO or SO₂.

16. Use of a compound according to Claims 13 or 14, wherein V is O or NH; a is 0 or 1; b is 1 or 2 and c is 1 or 2.


17. Use of a compound according to any one of Claims 1-11, wherein A is selected from the following groups which may be substituted by one, two or more fluorine atoms or by an alkyl group which may be substituted by one or more fluorine atoms, and wherein the amino groups may be substituted by an alkyl or an acyl group:

10






18. Use of a compound according to any one of claims 1-6 and 8-10, wherein the compound is represented by Formula (II):



wherein

10 L is selected from following groups:



b is 1, 2 or 3;

15

c is 1, 2 or 3;

20 R7 is hydrogen, a group of formula $\text{PO}_3\text{R}^9{}_2$ or SO_3R^{10} or a heteroalkyl group carrying at least one OH, NH₂, SO_3R^{10} , $\text{PO}_3\text{R}^9{}_2$ or COOH group, wherein R⁹ is H, alkyl, cycloalkyl, aryl, aralkyl, and wherein R¹⁰ is H, alkyl, cycloalkyl, aryl, aralkyl;


X, Y, Z, R1, R2, R3, R5, R6, R8, and the possible linkage between R3 and R5 are as defined above;

5 or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof for the treatment of anthrax.

10 19. Use of compounds according to Claim 18, wherein R7 is hydrogen or a group of the formula SO_3H , PO_3H_2 , $\text{PO}_3(\text{CH}_2\text{C}_6\text{H}_5)_2$, $\text{CH}_2\text{OPO}_3\text{H}$ or $\text{COCH}_2\text{CH}_2\text{COOH}$, or together with the oxygen to which it is bound forms an ester of a naturally occurring amino acid or a derivative thereof.

15 20. Use of compounds according to Claims 18 or 19, wherein R8 is a group of the formula $-\text{CH}_2\text{NHCOCH=CHAr}_1$, $-\text{CH}_2\text{OHeteroaryl}$, $-\text{CH}_2\text{NHSO}_2\text{Me}$, $-\text{CH}_2\text{NHCOOMe}$, $-\text{CH}_2\text{NHCS}_2\text{Me}$, $-\text{CH}_2\text{NHCSNH}_2$, $-\text{CH}_2\text{NHCSOMe}$ or $-\text{CH}_2\text{NHCOMe}$.

20 21. Use of compounds according to any one of Claims 18-20, wherein L is a group of the following formula:



25 22. Use of compounds according to any one of Claims 18-21, wherein R5 is H, F, Cl or a methoxy group which may be substituted by one, two or three fluorine atoms.

23. Use of compounds according to any one of Claims 18-22, wherein Z is CH_2 or CH_2CH_2 .

24. Use of a pharmaceutical composition containing a compound according to any one of the preceding claims and optionally carriers and/or adjuvants and/or diluents for the treatment of anthrax.

5

25. Use of pro-drugs, which contain a compound according to any one of the preceding claims and at least one pharmacologically acceptable protective group for the treatment of anthrax.

10

26. Use of a compound, a pharmaceutical composition or a pro-drug according to any one of the preceding claims for the manufacture of medicaments for the treatment of anthrax.

15

27. Use of a compound, a pharmaceutical composition or a pro-drug according to any one of the preceding claims for the treatment of infections.